Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2024-03-25 Major Shareholding Noti…
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
LENZ THERAPEUTICS, INC.
Major Shareholding Notification
2024-03-25 English
4
Director's Dealing
2024-03-25 English
3
Director's Dealing
2024-03-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by LENZ Therapeutics, Inc. dated March 21, 2024. It details the completion of a merger transaction, including a reverse stock split, name change, issuance of shares, and PIPE financing. The content focuses on the announcement of the completion of acquisition and related corporate actions. There are no financial statements or detailed financial performance data presented, nor is this a proxy statement or a solicitation document. The document is a regulatory announcement of a significant corporate event (merger completion and related capital changes). Form 8-K filings reporting such events are best classified under Regulatory Filings (RNS) as they are general regulatory announcements that do not fit other specific categories like M&A filings (which are typically Form 425, DEFM14A, SC 14D9, etc.) or Capital/Financing Updates (which focus more narrowly on financing activities). This document primarily reports the merger completion and related corporate actions in a regulatory filing format.
2024-03-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a merger agreement, stockholder approval of a reverse stock split and name change, and related corporate actions. It includes details about the merger, stock split ratio, effective dates, and trading symbol changes. There are no financial statements or detailed financial analysis included, only disclosures about corporate actions and merger-related events. This type of filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing significant corporate events but does not contain the full financial data or detailed report content that would classify it as an Annual Report, Interim Report, or other specific financial report. The document length (over 10,000 characters) and detailed disclosures confirm it is not a brief announcement or certification but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2024-03-19 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Graphite Bio, Inc. It details the submission of matters to a vote of security holders related to a merger agreement, including the voting results on several proposals at a special meeting. The content focuses on the official results of shareholder votes on merger-related proposals, including stock issuance, reverse stock split, name change, equity incentive plan, and employee stock purchase plan. The document does not contain financial statements or detailed financial analysis but reports the voting outcomes. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is over 12,000 characters, indicating it is not a brief announcement but a full voting result report. Therefore, the correct classification is DVA with high confidence.
2024-03-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.